본문 바로가기
KERD
논문KCI 등재

Chemotherapy for Advanced Gastric Cancer: Review and Update of Current Practices

전훈재|박성철
거트앤리버 소화기연관학회협의회|2013.07|Gut and Liver|제7권 제4호|pp. 385-393

1

조회

0

다운로드

1

인용

0

참고문헌

키워드

Stomach neoplasms; Drug therapy

초록

No standard adjuvant or palliative chemotherapy regimen has been internationally approved for patients with advanced gastric cancer. Adjuvant chemoradiotherapy is administered prior to surgery and is used in the Unitied States, and intensified chemotherapy is administered prior to and after surgery and is used in Europe. Limited D1 dissections are also frequently performed in the United States and Europe. In Korea, patients undergoing D2 resection appear to benefit from postoperative adjuvant chemotherapy using S-1or capecitabine plus oxaliplatin. Fluoropyrimidine, platinum,taxane, epirubicin, and irinotecan may be employed alone or in combination as a first-line therapy in a palliative chemotherapy regimen. In Asia, an orally administered fluoropyrimidine,such as capecitabine or S-1, is favored over the continuous infusion of 5-fluorouracil because of its convenience. Trastuzumab has been integrated into the current standard chemotherapy for human epidermal growth factor receptor 2-overexpressing gastric cancers. There is currently no standard regimen for secondary palliative chemotherapy. Clinical studies of several targeted therapies are ongoing.

Abstract

No standard adjuvant or palliative chemotherapy regimen has been internationally approved for patients with advanced gastric cancer. Adjuvant chemoradiotherapy is administered prior to surgery and is used in the Unitied States, and intensified chemotherapy is administered prior to and after surgery and is used in Europe. Limited D1 dissections are also frequently performed in the United States and Europe. In Korea, patients undergoing D2 resection appear to benefit from postoperative adjuvant chemotherapy using S-1or capecitabine plus oxaliplatin. Fluoropyrimidine, platinum,taxane, epirubicin, and irinotecan may be employed alone or in combination as a first-line therapy in a palliative chemotherapy regimen. In Asia, an orally administered fluoropyrimidine,such as capecitabine or S-1, is favored over the continuous infusion of 5-fluorouracil because of its convenience. Trastuzumab has been integrated into the current standard chemotherapy for human epidermal growth factor receptor 2-overexpressing gastric cancers. There is currently no standard regimen for secondary palliative chemotherapy. Clinical studies of several targeted therapies are ongoing.

참고문헌 (53)

  1. Garcia M, "Global cancer facts & figures 2007" (2007), American Cancer Society
  2. Kyu-Won Jung, "Cancer Statistics in Korea: Incidence, Mortality, Survival, and Prevalence in 2009", Cancer Research and Treatment, 44(1), pp.11~24 (2012), 대한암학회
  3. Strong VE, "Comparison of gastric cancer survival following R0 resection in the United States and Korea using an internationally validated nomogram", Ann Surg, 251, pp.640~646 (2010)
  4. Ohtsu A, "Disparities in gastric cancer chemotherapy between the East and West", J Clin Oncol, 24, pp.2188~2196 (2006)
  5. Roviello F, "Prospective study of peritoneal recurrence after curative surgery for gastric cancer", Br J Surg, 90, pp.1113~1119 (2003)
  6. Janunger KG, "SBU-group Swedish Council of Technology Assessment in Health Care. A systematic overview of chemotherapy effects in gastric cancer", Acta Oncol, 40, pp.309~326 (2001)
  7. Mari E, "Efficacy of adjuvant chemotherapy after curative resection for gastric cancer: a meta-analysis of published randomised trials. A study of the GISCAD (Gruppo Italiano per lo Studio dei Carcinomi dell’Apparato Digerente)", Ann Oncol, 11, pp.837~843 (2000)
  8. GASTRIC (Global Advanced, "Adjuvant Stomach Tumor Research International Collaboration) Group", Benefit of adjuvant chemotherapy for resectable gastric cancer: a meta-analysis, 2010, pp.303, 1729~1737
  9. Cunningham D, "Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer", N Engl J Med, 355, pp.11~20 (2006)
  10. Macdonald JS, "Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction", N Engl J Med, 345, pp.725~730 (2001)
  11. Sasako M, "Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer", J Clin Oncol, 29, pp.4387~4393 (2011)
  12. "Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial", LANCET, 379(9813), pp.315~321 (2012), ELSEVIER SCIENCE INC
  13. Fuchs CS, "Postoperative adjuvant chemoradiation for gastric or gastroesophageal junction (GEJ) adenocarcinoma using epirubicin, cisplatin, and infusional (CI) 5-FU (ECF) before and after CI 5-FU and radiotherapy (CRT) compared with bolus 5-FU", LV before and after CRT: intergroup trial CALGB 80101, 2011, pp.29(15 Suppl), abstr 4003~
  14. Songun I, "Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial", Lancet Oncol, 11, pp.439~449 (2010)
  15. Bajetta E, "Intergroup Trial of Adjuvant Chemotherapy in Adenocarcinoma of the Stomach (ITACA-S) trial: comparison of a sequential treatment with irinotecan (CPT-11) plus 5-fluorouracil (5-FU)", folinic acid (LV) followed by docetaxel and cisplatin versus a 5-FU, J Clin Oncol, pp.2012, 30(18 Suppl)[DOI]
  16. Ychou M, "Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial", J Clin Oncol, 29, pp.1715~1721 (2011)
  17. "Phase III Trial Comparing Capecitabine Plus Cisplatin Versus Capecitabine Plus Cisplatin With Concurrent Capecitabine Radiotherapy in Completely Resected Gastric Cancer With D2 Lymph Node Dissection: The ARTIST Trial", JOURNAL OF CLINICAL ONCOLOGY, 30(3), pp.268~273 (2012), AMER SOC CLINICAL ONCOLOGY
  18. Yan TD, "A systematic review and meta-analysis of the randomized controlled trials on adjuvant intraperitoneal chemotherapy for resectable gastric cancer", Ann Surg Oncol, 14, pp.2702~2713 (2007)
  19. Kang YK, "Update of AMC 0101 study: a phase III trial of intraperitoneal cisplatin and early mitomycin-C plus long-term doxifluridine plus cisplatin (iceMFP) versus mitomycin-C plus short-term doxifluridine (Mf) as adjuvant chemotherapy for grossly serosa-positive advanced gastric cancer (NCT00296322)", J Clin Oncol, 30(4 Suppl 4), pp.abstr 4~ (2012)
  20. Ryoo BY, "Update of AMC 0201 study: a randomized phase III trial comparing mitomycin-C plus short-term doxifluridine (Mf) versus mitomycin-C plus long-term doxifluridine plus cisplatin (MFP) after curative resection of advanced gastric cancer (NCT00296335)", J Clin Oncol, 30(4 Suppl), pp.abstr 76~ (2012)
  21. "Gastric cancer 2012" (2013)[URL]
  22. Kim SJ, "Safety, compliance, and predictive parameters for dosage modification in adjuvant S-1 chemotherapy for gastric cancer", Cancer Sci, 104, pp.116~123 (2013)
  23. 류민희, "위암의 보조항암화학요법", 대한내과학회지, 83(3), pp.291~296 (2012), 대한내과학회[DOI]
  24. Wagner AD, "Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data", J Clin Oncol, 24, pp.2903~2909 (2006)
  25. Wagner AD, "Chemotherapy for advanced gastric cancer", Cochrane Database Syst Rev, (3), pp.CD004064~ (2010)
  26. Van Cutsem E, "Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group", J Clin Oncol, 24, pp.4991~4997 (2006)
  27. Cunningham D, "Capecitabine and oxaliplatin for advanced esophagogastric cancer", N Engl J Med, 358, pp.36~46 (2008)
  28. "Capecitabine", cisplatin versus 5-fluorouracil, ANNALS OF ONCOLOGY, pp.2009, 20(4)[DOI]
  29. Koizumi W, "S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial", Lancet Oncol, 9, pp.215~221 (2008)
  30. Okines AF, "Meta-analysis of the REAL-2 and ML17032 trials: evaluating capecitabine-based combination chemotherapy and infused 5-fluorouracil-based combination chemotherapy for the treatment of advanced oesophago-gastric cancer", Ann Oncol, 20, pp.1529~1534 (2009)
  31. Webb A, "Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer", J Clin Oncol, 15, pp.261~267 (1997)
  32. Al-Batran SE, "Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie", J Clin Oncol, 26, pp.1435~1442 (2008)
  33. Dank M, "Randomized phase III study comparing irinotecan combined with 5-fluorouracil and folinic acid to cisplatin combined with 5-fluorouracil in chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction", Ann Oncol, 19, pp.1450~1457 (2008)
  34. Fujii M, "Randomized phase III study of S-1 alone versus S-1 plus docetaxel (DOC) in the treatment for advanced gastric cancer (AGC): the START trial update", J Clin Oncol, 29(15 Suppl), pp.abstr 4016~ (2011)
  35. Van Cutsem E, "Randomized phase II study (GATE study) of docetaxel plus oxaliplatin with or without fluorouracil or capecitabine in metastatic or locally recurrent gastric cancer", J Clin Oncol, 29(15 Suppl), pp.abstr 4018~ (2011)
  36. Shah MA, "Random assignment multicenter phase II study of modified docetaxel, cisplatin, fluorouracil (mDCF) versus DCF with growth factor support (GCSF) in metastatic gastroesophageal adenocarcinoma (GE)", J Clin Oncol, 28(15 Suppl), pp.abstr 4014~ (2010)
  37. Park SR, "A randomized phase II study of continuous versus intermittent S-1 plus oxaliplatin in first-line treatment of patients with metastatic gastric carcinoma", J Clin Oncol, 30(15 Suppl), pp.abstr 4028~ (2012)
  38. Haller DG, "Potential regional differences for the tolerability profiles of fluoropyrimidines", J Clin Oncol, 26, pp.2118~2123 (2008)
  39. Ma BB, "Population-based differences in treatment outcome following anticancer drug therapies", Lancet Oncol, 11, pp.75~84 (2010)
  40. Gravalos C, "HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target", Ann Oncol, 19, pp.1523~1529 (2008)
  41. "Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial", Lancet, 376(9742), pp.687~697 (2010), ELSEVIER SCIENCE INC
  42. "Bevacizumab in Combination With Chemotherapy As First-Line Therapy in Advanced Gastric Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase III Study", JOURNAL OF CLINICAL ONCOLOGY, 29(30), pp.3968~3976 (2011), AMER SOC CLINICAL ONCOLOGY
  43. Van Cutsem E, "Phase III trial of everolimus (EVE) in previously treated patients with advanced gastric cancer (AGC): GRANITE-1", J Clin Oncol, 30(4 Suppl), pp.LBA3~ (2012)
  44. Waddell TS, "A randomized multicenter trial of epirubicin, oxaliplatin, and capecitabine (EOC) plus panitumumab in advanced esophagogastric cancer (REAL3)", J Clin Oncol, 30(18 Suppl), pp.LBA4000~ (2012)
  45. Shah MA, "Prognostic significance of human epidermal growth factor-2 (HER2) in advanced gastric cancer: A U.S. and European international collaborative analysis", J Clin Oncol, 29(15 Suppl), pp.abstr 4014~ (2011)
  46. Gordon MA, "Assessment of HER2 gene amplification in adenocarcinomas of the stomach or gastroesophageal junction in the INT-0116", SWOG9008 clinical trial, 2012, pp.30(15 Suppl), abstr 4010~
  47. Shah MA, "Survival analysis according to disease subtype in AVAGAST: First-line capecitabine and cisplatin plus bevacizumab (bev) or placebo in patients (pts) with advanced gastric cancer", J Clin Oncol, 30(4 Suppl), pp.abstr 5~ (2012)
  48. Van Cutsem E, "Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a biomarker evaluation from the AVAGAST randomized phase III trial", J Clin Oncol, 30, pp.2119~2127 (2012)
  49. Wakatsuki T, "Ethnic gene profile of genes involved in angiogenesis to predict regional bevacizumab efficacy difference in gastric cancer", J Clin Oncol, 30(15 Suppl), pp.abstr 4026~ (2012)
  50. Kilgour E, "Prevalence and prognostic significance of FGF receptor 2 (FGFR2) gene amplification in Caucasian and Korean gastric cancer cohorts", J Clin Oncol, 30(15 Suppl), pp.abstr 4124~ (2012)
  51. Thuss-Patience PC, "Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer: a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO)", Eur J Cancer, 47, pp.2306~2314 (2011)
  52. "Salvage Chemotherapy for Pretreated Gastric Cancer: A Randomized Phase III Trial Comparing Chemotherapy Plus Best Supportive Care With Best Supportive Care Alone", JOURNAL OF CLINICAL ONCOLOGY, 30(13), pp.1513~1518 (2012), AMER SOC CLINICAL ONCOLOGY
  53. Ueda S, "Randomized phase III study of irinotecan (CPT-11) versus weekly paclitaxel (wPTX) for advanced gastric cancer (AGC) refractory to combination chemotherapy (CT) of fluoropyrimidine plus platinum (FP): WJOG4007 trial", J Clin Oncol, 30(15 Suppl), pp.abstr 4002~ (2012)

관련 논문AI추천

Irinotecan Monotherapy Versus Irinotecan-Based Combination as Second-Line Chemotherapy in Advanced Gastric Cancer: A Meta-Analysis김수녕, 윤소영, 조요한대한암학회 · Cancer Research and Treatment2017 · 제49권 제1호Outcomes of Modified FOLFOX-6 as First Line Treatment in Patients with Advanced Gastric Cancer in a Single Institution; Retrospective Analysis김욱, 허훈, 김수홍, 박애령, 이한홍, 전해명대한암학회 · Cancer Research and Treatment2010 · 제42권 제1호Modified FOLFIRI as Second-Line Chemotherapy after Failure of Modified FOLFOX-4 in Advanced Gastric Cancer고윤호, 김태희, 노상영, 박지찬, 원혜성, 전은경, 정승은, 홍숙희, 홍영선대한암학회 · Cancer Research and Treatment2011 · 제43권 제3호Prognostic Factors of Second and Third Line Chemotherapy Using 5-FU with Platinum, Irinotecan, and Taxane for Advanced Gastric Cancer고희성, 김민경, 김종원, 박승교, 박지수, 윤선옥, 임재윤, 조재용, 최승호대한암학회 · Cancer Research and Treatment2011 · 제43권 제4호위암의 맞춤 항암 요법의 최신 지견라선영, 정희철대한내과학회 · 대한내과학회지2009 · 제77권 제1호A Multicenter Randomized Phase II Study of Docetaxel vs. Docetaxel Plus Cisplatin vs. Docetaxel Plus S-1 as Second-Line Chemotherapy in Metastatic Gastric Cancer Patients Who Had Progressed after Cisplatin Plus Either S-1 or Capecitabine김미정, 김범준, 김진원, 박숙련, 박영이, 이근욱, 한혜숙대한암학회 · Cancer Research and Treatment2017 · 제49권 제3호

이 간행물의 다른 논문 (19건)

Recent Advances in the Diagnosis and Management of Autoimmune Pancreatitis: Similarities and Differences in Japan and KoreaTooru Shimosegawa, 김명환, 정재복, 류지곤, Terumi Kamisawa, Kazuichi Okazakipp. 394-400Lichen Planus Is an Uncommon Cause of Nonspecific Proximal Esophageal InflammationMatthew S. Linton, Liena Zhao, Xianyong Gui, Martin Storr, Christopher N. Andrewspp. 401-405Levofloxacin, Metronidazole, and Lansoprazole Triple Therapy Compared to Quadruple Therapy as a Second-Line Treatment of Helicobacter pylori Infection in Korea정정임, 송근암, 정재훈, 문지윤, 송철수, 유현석, 이봉은, 김광하, 류동엽pp. 406-410Proteomic Identification of Proteins Suggestive of Immune-Mediated Response or Neuronal Degeneration in Serum of Achalasia Patients이광재, 임선교, Mari Yeopp. 411-416Effects of the Temporary Placement of a Self-Expandable Metallic Stent in Benign Pyloric Stenosis김지훈, 김재선, 김성호, 최우석, 임은혜, 윤재원, 노혜진, 박영태, 이범재, 변관수, 박종재, 연종은, 주문경, 최원재, Jain Parkpp. 417-422
원문 보기